PTO/SB/30 (01-09) Approved for use through 02/28/2009. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are requi	U.S. Patent and Trad- red to respond to a collection of inform	emark Office; U.S. DEPARTMENT OF COMME nation unless it contains a valid OMB control nu	mber
Request	Application Number	10/535,366	~
for	Filing Date	5/18/2005	
Continued Examination (RCE) Transmittal	First Named Inventor	Takashi Abe	
Address to:	Art Unit	2622	
Mail Stop RCE Commissioner for Patents	Examiner Name	Amy R. Hsu	
P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket Number	09792909-6253	
his is a Request for Continued Examination (RCS) counter for Continued Examination (RCS) exaction under \$70 ct 995, or to any design application. See instruction Sheet for RCS etc. (RCS) and the seed of the RCS etc. (RCS) etc. (RCS	FR 1.114 does not apply to any ut Es (not to be submitted to the USE te: If the RCE is proper, any provio order in which they were filed un order anendment() entered, apply ubstanding, any amendments file mot checked. lef or Reply Brief previously filed iii Information	utility or plant application filed prior to June SPTO) on page 2. cousty filed unentered amendments and neless applicant instructs otherwise. If olicant must request non-entry of such ad after the final Office action may be	18,
a. Suspension of action on the above-identified a period of months. (Period of suspens b. Other	ion shall not exceed 3 months; Fee un	nder 37 CFR 1.17(i) required)	
The RCE fee under 37 CFR 1.17(e) is require The Director is hereby authorized to charge th Deposit Account No. 19-3140 i. V RCE fee required under 37 CFR 1.17(e)			0
ii. Extension of time fee (37 CFR 1.136 and 1.	17)		
iii. Other			
b. Check in the amount of \$	enclosed		
c. Payment by credit card (Form PTO-2038 enclose	•		
ARNING: Information on this form may become public. Cr and information and authorization on PTO-2038.	edit card information should no	ot be included on this form. Provide on	edit
		FOUIRED	_
SIGNATURE OF APPLICA			
gnature /Adam C. Rehm/	Date	e February 17, 2009	_
gnature //Adam C. Rehm/ ame (Print/Type) Adam C. Rehm	Date Reg	e February 17, 2009 pistration No. 54,797	
gnature //Adam C. Rehm/ ame (Print/Type) Adam C. Rehm	Date	e February 17, 2009 pistration No. 54,797	_
gnature //dam C. Rehm/ ame (Print/Type) Adam C. Rehm CERTIFICATE OI ereby certify that this correspondence is being deposited with the Unite dressed to Mail Stop RCE, Commissioner for Patents, P. O. Box 1450 floc on the date shown below.	Date Reg FMAILING OR TRANSMISSION d States Postal Service with sufficient	e February 17, 2009 pistration No. 54,797 t postage as first class mail in an envelope	ark
ignature //Adam C. Rehm/ ame (Print/Type) Adam C. Rehm	Date Reg FMAILING OR TRANSMISSION d States Postal Service with sufficient	e February 17, 2009 jistration No. 54,797 t postage as first class mail in an envelope nale transmitted to the U.S. Patent and Tradema	ark

the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chef Information Officer. U.S. Patient and Trademark Office, U.S. Depatiment of Commence, P.O. Box, 1450, Alexandriv, V.A. 2231-1450. DON OT SEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patients, P.O. Box 1450, Alexandris, V.A. 2231-1450. DON 1450 APRIL 2231-1450. If you need assistance in completing the form, all 1-900-PTO-1999 and select option 2.

Instruction Sheet for RCEs (not to be submitted to the USPTO)

NOTES:

An RCE is not a new application, and filing an RCE will not result in an application being accorded a new filing date

Filing Qualifications:

The application must be a utility or plant application filed on or after June 8, 1995. The application cannot be a provisional application, a utility or plant application filed before June 8, 1995, a design application, or a patent under reexamination. See 37 CFR 1 114(e)

Filing Requirements:

Prosecution in the application must be closed. Prosecution is closed if the application is under appeal, or the last Office action is a final action, a notice of allowance, or an action that otherwise closes prosecution in the application (e.g., an Office action under Ex parte Quayle). See 37 CFR 1.114(b).

A submission and a fee are required at the time the RCE is filed. If reply to an Office action under 35 U.S.C. 132 is outstanding (e.g., the application is under final rejection), the submission must meet the reply requirements of 37 CFR 1.111. If there is no outstanding Office action, the submission can be an information disclosure statement, an amendment, new arguments, or new evidence. See 37 CFR 1.114(c). The submission may be a previously filed amendment (e.g., an amendment after final rejection).

WARNINGS:

Request for Suspension of Action:

All RCE filing requirements must be met before suspension of action is granted. A request for a suspension of action under 37 CFR 1.103(c) does not satisfy the submission requirement and does not permit the filing of the required submission to be suspended.

Improper RCE will NOT toll Any Time Period:

Before Appeal - If the RCE is improper (e.g., prosecution in the application is not closed or the submission or fee has not been filed) and the application is not under appeal, the time period set forth in the last Office action will continue to run and the application will be abandoned after the statutory time period has expired if a reply to the Office action is not timely filed. No additional time will be given to correct the improper RCE.

Under Appeal - If the RCE is improper (e.g., the submission or the fee has not been filed) and the application is under appeal, the improper RCE is effective to withdraw the appeal. Withdrawal of the appeal results in the allowance or abandonment of the application depending on the status of the claims. If there are no allowed claims, the application is abandoned. If there is at least one allowed claim, the application will be passed to issue on the allowed claim(s). See MPEP 1215.01.

See MPEP 706.07(h) for further information on the RCE practice.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S. (2b)(2), (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration or the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S. C. 552) and the Privacy Act (6 U.S. C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.